Abstract

BackgroundBesides major clinical/biochemical features, neutropenia and inflammatory bowel disease (IBD) constitute common complications of Glycogen storage disease type Ib (GSD Ib). However, their management is still challenging. Although previous reports have shown benefit of empagliflozin administration on neutropenia, no follow-up data on bowel (macro/microscopic) morphology are available. We herein present for the first time longitudinal assessment of bowel morphology in a GSD Ib child suffering from Crohn disease-like enterocolitis treated with empagliflozin.Case presentationA 14-year-old boy with GSD Ib and severe IBD was (off-label) treated with empagliflozin (20 mg/day) after informed oral and written consent was obtained from the patient’s parents. No adverse events were noted. Clinical symptoms and stool frequency improved within the first week of treatment. Pediatric Crohn disease activity index (PCDAI) normalised within the first month of treatment. Abdomen magnetic resonance imaging (MRI) performed 3 months after treatment initiation showed dramatic decrease in disease activity and length. Similar findings were reported on histology at 5.5 months. At 7.5 months hemoglobin levels normalised and fecal calprotectin almost normalised. Improved neutrophil count, metabolic control and quality of life were also noted. G-CSF dose was decreased by 33% and the patient was partly weaned from tube feeding.ConclusionsThis is the first report presenting extensive gastrointestinal morphology follow-up in a GSD Ib patient receiving empagliflozin. The present case suggests that empagliflozin can be safe and effective in inducing IBD remission in GSD Ib patients and can even postpone surgery. Future studies are required to confirm its effect over time and assess its benefit in various disease stages. The development of an international collaborating networks for systematic data collection is worthy.

Highlights

  • Besides major clinical/biochemical features, neutropenia and inflammatory bowel disease (IBD) constitute common complications of Glycogen storage disease type Ib (GSD Ib)

  • The present case suggests that empagliflozin can be safe and effective in inducing IBD remission in GSD Ib patients and can even postpone surgery

  • While evidence regarding the pathogenesis of neutropenia/neutrophil dysfunction and autoimmune disorders has accumulated [7,8,9], the pathomechanism of IBD in GSD Ib is still unclear; the disturbed immune response may play a role in its pathogenesis [4]

Read more

Summary

Introduction

Besides major clinical/biochemical features, neutropenia and inflammatory bowel disease (IBD) constitute common complications of Glycogen storage disease type Ib (GSD Ib). Glycogen storage disease type Ib (GSD Ib, MIM#232220) is an inherited disorder of carbohydrate metabolism due to microsomal glucose-6-phosphate transporter (G6PT) deficiency (SLC37A4 gene). GSD Ib patients show neutropenia/neutrophil dysfunction [3] and increased risk of inflammatory bowel disease (IBD) (i.e., Crohn disease-like enterocolitis) [4], and autoimmune disorders [5, 6]. Granulocyte-colony stimulating factor (GCSF) for neutropenia and conventional drugs for IBD and autoimmune disorders still constitute the current treatment options for most GSD Ib patients. Improved prevention/ treatment of IBD in GSD Ib ranked as a top priority for research in the international priority setting partnership for liver glycogen storage diseases [10]

Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call